These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32843146)

  • 1. Bretylium, a Class III Antiarrhythmic, Returns to the Market.
    Thind M; Sullivan RM; Williams RN; Kowey PR
    Am J Cardiol; 2020 Oct; 133():77-80. PubMed ID: 32843146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale of therapy in the patient with acute myocardial infarction and life-threatening arrhythmias: a focus on bretylium.
    Lucchesi BR
    Am J Cardiol; 1984 Jul; 54(2):14A-19A. PubMed ID: 6380259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bretylium tosylate: profile of the only available class III antiarrhythmic agent.
    Anderson JL
    Clin Ther; 1985; 7(2):205-24. PubMed ID: 3886143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bretylium: a prototype for future development of antidysrhythmic agents.
    Patterson E; Lucchesi BR
    Am Heart J; 1983 Aug; 106(2):426-31. PubMed ID: 6869235
    [No Abstract]   [Full Text] [Related]  

  • 5. Advanced cardiac life support controversy: where do antiarrhythmic agents fit in?
    Chow MS
    Pharmacotherapy; 1997; 17(2 Pt 2):84S-88S; discussion 89S-91S. PubMed ID: 9085344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias.
    Heissenbuttel RH; Bigger JT
    Ann Intern Med; 1979 Aug; 91(2):229-38. PubMed ID: 380436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bretylium tosylate: a review.
    Bryan CK; Darby MH
    Am J Hosp Pharm; 1979 Sep; 36(9):1189-92. PubMed ID: 386786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New perspectives in the pharmacologic therapy of cardiac arrhythmias.
    Singh BN; Collett JT; Chew CY
    Prog Cardiovasc Dis; 1980; 22(4):243-301. PubMed ID: 6986060
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias.
    Nolan PE
    Pharmacotherapy; 1997; 17(2 Pt 2):65S-75S; discussion 89S-91S. PubMed ID: 9085342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of ventricular dysrhythmias in the prehospital and emergency department setting.
    Mayer NM
    Am J Cardiol; 1984 Jul; 54(2):34A-36A. PubMed ID: 6464998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs.
    Koerner JE; Dage RC
    J Cardiovasc Pharmacol; 1990 Sep; 16(3):383-93. PubMed ID: 1700208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of chronic canine ventricular tachyarrhythmias with bretylium tosylate.
    Patterson E; Gibson JK
    Circulation; 1981 Nov; 64(5):1045-50. PubMed ID: 7285294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for treatment of ventricular arrhythmias.
    Heger JJ; Prystowsky EN; Zipes DP
    Heart Lung; 1981; 10(3):475-83. PubMed ID: 6785255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bretylium tosylate.
    Cooper JA; Frieden J
    Am Heart J; 1971 Nov; 82(5):703-6. PubMed ID: 4940224
    [No Abstract]   [Full Text] [Related]  

  • 15. Arrhythmia and acute coronary syndrome suppression and cardiac resuscitation management with bretylium.
    Bacaner M; Dembo DH
    Am J Ther; 2009; 16(6):534-42. PubMed ID: 19542875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic agents. I. Mechanisms of action and clinical pharmacology.
    Mason DT; DeMaria AN; Amsterdam EA; Zelis R; Massumi RA
    Drugs; 1973; 5(4):261-91. PubMed ID: 4146767
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group.
    Kowey PR; Levine JH; Herre JM; Pacifico A; Lindsay BD; Plumb VJ; Janosik DL; Kopelman HA; Scheinman MM
    Circulation; 1995 Dec; 92(11):3255-63. PubMed ID: 7586312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiarrhythmic and antifibrillatory actions of bretylium and its o-iodobenzyl trimethylammonium analog, UM-360.
    Kniffen FJ; Lomas TE; Counsell RE; Lucchesi BR
    J Pharmacol Exp Ther; 1975 Jan; 192(1):120-8. PubMed ID: 1123718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of bretylium and clofilium on dispersion of refractoriness and vulnerability to ventricular fibrillation in the ischemic feline heart.
    Kowey PR; Friehling TD; O'Connor KM; Wetstein L; Kelliher GJ
    Am Heart J; 1985 Aug; 110(2):363-70. PubMed ID: 4025111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.
    Anderson JL
    Am J Cardiol; 1984 Jul; 54(2):7A-13A. PubMed ID: 6147079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.